Targeted Oncology· @TargetedOnc · X·· 15 小时前评分70
正文 · 机器翻译
#ESMO26 的 KRAS G12D 数据令人鼓舞！
QTX3034 + cetuximab：ORR 26%，DCR 79%（n=19）。
加用 FOLFOX：4 例中有 2 例应答。
但 FOLFOX 的增量获益是什么？KRAS/EGFR 双重阻断能否在不联合化疗的情况下实现持久控制？
早期数据——还有重要问题需要解答。
126 浏览 · 2 赞 · 1 转发 · 0 回复
会议摘要
788RO按 Rapid oral: Gastrointestinal tumours, lower digestive 对上
Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
https://esmocongress.esmo.orgNCT06578559NCT06578559按 - **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC 对上
- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
https://esmocongress.esmo.orgNCT06640166NCT06640166按 - **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. 对上
- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
https://esmocongress.esmo.org来源：Targeted Oncology · x.com